Literature DB >> 16095475

Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia.

K Bronnick1, D Aarsland, J P Larsen.   

Abstract

OBJECTIVE: To investigate the inter-relationship of neuropsychiatric disturbances in Parkinson's disease (PD) by cluster analysis and describe the properties of the clusters.
METHOD: A total of 139 patients were assessed using the neuropsychiatric inventory (NPI). A cluster-analysis was used to investigate the inter-relationship of NPI items. The clusters were profiled regarding dementia (PDD) and major depression.
RESULTS: A total of 39 patients showed no neuropsychiatric symptoms. The remaining 100 patients (43% PDD) were divided in to five clusters. The largest group (42, 31% PDD) showed symptoms of mild depression, followed by a group (29, 79.3% PDD) with hallucinations and mild other symptoms. The third group (14, 7.1% PDD) had sleep disturbances exclusively. The fourth group (8, 25% PDD) showed apathy, anxiety and depression. The smallest group (7, 57.1% PDD) had high scores on several NPI items.
CONCLUSION: Our PD sample can be divided in to clusters based on the NPI, with different prevalence of dementia and depression. Copyright (c) 2005 Blackwell Munksgaard

Entities:  

Mesh:

Year:  2005        PMID: 16095475     DOI: 10.1111/j.1600-0447.2005.00562.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  17 in total

1.  Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients.

Authors:  Roberto Erro; Gabriella Santangelo; Marina Picillo; Carmine Vitale; Marianna Amboni; Katia Longo; Angela Costagliola; Maria Teresa Pellecchia; Roberto Allocca; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Paolo Barone
Journal:  J Neurol       Date:  2012-02-07       Impact factor: 4.849

2.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

Review 3.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Management of Parkinson's disease dementia : practical considerations.

Authors:  Arvid Rongve; Dag Aarsland
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.

Authors:  D Aarsland; K Brønnick; U Ehrt; P P De Deyn; S Tekin; M Emre; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-07-04       Impact factor: 10.154

6.  The impact of sleep quality on cognitive functioning in Parkinson's disease.

Authors:  Karina Stavitsky; Sandy Neargarder; Yelena Bogdanova; Patrick McNamara; Alice Cronin-Golomb
Journal:  J Int Neuropsychol Soc       Date:  2011-12-09       Impact factor: 2.892

7.  Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.

Authors:  Jisook Moon; Hyun-Seob Lee; Jun Mo Kang; Junpil Park; Amanda Leung; Sunghoi Hong; Sangmi Chung; Kwang-Soo Kim
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

Review 8.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 9.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

10.  Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease.

Authors:  Paul Ardayfio; Jisook Moon; Ka Ka Amanda Leung; Dong Youn-Hwang; Kwang-Soo Kim
Journal:  Neurobiol Dis       Date:  2008-06-04       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.